# Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention

> **NCT03517995** · PHASE2 · WITHDRAWN · sponsor: **H. Lee Moffitt Cancer Center and Research Institute**

## Conditions studied

- Bladder Cancer
- Bladder Tumor
- Urothelial Carcinoma

## Interventions

- **DRUG:** Sulforaphane Administration
- **OTHER:** Placebo Administration
- **PROCEDURE:** Standard of Care Surgery

## Key facts

- **NCT ID:** NCT03517995
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-04
- **Primary completion:** 2021-12
- **Final completion:** 2022-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Grant not approved
- **Last updated:** 2020-05-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03517995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03517995, "Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03517995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*